Ioversol
- Atc Codes:V08AB07
- CAS Codes:87771-40-2
- PHARMGKB ID:87771-40-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Drug Interactions
- Dosage
Brand Names
Europe
Austria: Optiray; Belgium: Optiject, Optiray; Czech Republic: Optiray; Denmark: Optiray; Finland: Optiray; France: Optiject, Optiray; Germany: Optiject, Optiray; Greece: Optiray; Hungary: Optiray; Ireland: Optiray; Italy: Optiray; Luxembourg: Optiject; Netherlands: Optiray; Poland: Optiray; Romania: Optiray; Slovakia: Optiray; Spain: Optiray; Sweden: Optiray.
North America
Canada: Optiray; USA: Optiray.
Asia
Japan: Optiray.
Drug combinations
Chemistry
Ioversol: C~18~H~24~I~3~N~3~O~9~. Mw: 807.11. (1) 1,3-Benzenedicarboxamide, N,N’-bis(2,3-dihydroxypropyl)-5-[(hydroxyacetyl)(2-hydroxyethyl)amino]-2,4,6-triiodo-; (2) N,N’-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxyethyl)glycolamido]-2,4,6-triiodoisophthalamide. CAS-87771-40-2 (1987).
Pharmacologic Category
Diagnostic Agents; Imaging Agents; Iodinated Contrast Media. Radiological/Contrast Media (Nonionic, Low Osmolality). (ATC-Code: V08AB07).
Mechanism of action
Therapeutic use
Arteriography, angiography, angiocardiography, ventriculography, excretory urography, and venography procedures. Contrast-enhanced tomographic imaging.
Pregnancy and lactiation implications
Teratogenic effects not observed in animal studies. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to any component of the formulation. Not for intrathecal use.